The Association Between Vascular Endothelial Growth Factor (VEGF) Levels And Prognosis In Patients Chronic Lymphocytic Leukemia

INTRODUCTION: The Rai and Binet staging systems are used as a standard method to evaluate the prognosis of chronic lympocytic leukemia (CLL). However, CLL is a heterogeneous disease in terms of clinical features and prognosis. The Rai and Binet staging systems; may not reflect the different biological properties of CLL cells affecting survival outcomes and response to treatment. Because of this, new prognostic parameters has become important in the recent years. It is suggested that serum VEGF levels in CLL may be an important parameter in determining the progression of the disease. METHODS: We detected the serum levels of VEGF in 46 CLL patients and 20 healthy controls with the use of ELİSA method. RESULTS: The CLL patients group had higher median serum levels of VEGF compared to the control group (267 pg / mL, 43,8 pg/mL, p: 267 pg/ml) were associated with a shorter time of disease progression in Binet A and B CLL patients (p: 0,004). We also found that high serum VEGF levels showed a significant correlation with OS (p: 0,019). DISCUSSION and CONCLUSION: As a result, we found that the serum levels of VEGF in the CLL patients are higher than the control group and it can be a parameter associated with the disease progression and survival. For this reason and because the simplicity of analyzing with ELISA, it can be a useful clinical parameter, after its importance have been shown in larger and multi-variate studies.

Kronik Lenfositik Lösemi Tanılı Hastalarda Vasküler Endotel Büyüme Faktör (VEGF) Düzeylerinin Prognozla İlişkisi

GİRİŞ ve AMAÇ: Rai ve Binet evreleme sistemleri, kronik lenfositik lösemi (KLL)'nin prognozunu değerlendirmek için standart bir yöntem olarak kullanılırlar. Bununla birlikte, KLL klinik özellikler ve prognoz açısından heterojen bir hastalıktır. Rai ve Binet evreleme sistemleri; sağkalım sonuçlarını ve tedaviye cevabı etkileyen KLL hücrelerinin farklı biyolojik özelliklerini yansıtmayabilir. Bu nedenle, son yıllarda yeni prognostik parametreler önemli hale gelmiştir. KLL'deki serum VEGF düzeylerinin, hastalığın ilerlemesini belirlemede önemli bir parametre olabileceği önerilmektedir. YÖNTEM ve GEREÇLER: 46 KLL hastasında ve 20 sağlıklı kontrolde; serum VEGF düzeylerini ELISA yöntemi ile tespit ettik. BULGULAR: KLL hasta grubunda; sağlıklı kontrol grubuna göre daha yüksek ortalama serum VEGF düzeyleri saptandı (sırasıyla; 267 pg / mL, 43,8 pg/mL, p: 267 pg / ml), Binet A ve B KLL hastalarında daha kısa hastalık progresyonu süresi ile ilişkiliydi (p: 0,004). Ayrıca yüksek serum VEGF düzeylerinin OS ile anlamlı korelasyon gösterdiğini saptadık (p: 0,019). TARTIŞMA ve SONUÇ: Sonuç olarak, KLL hastalarındaki serum VEGF düzeylerinin kontrol grubundan daha yüksek olduğunu ve hastalığın ilerlemesi ve sağkalımı ile ilişkili bir parametre olabileceğini bulduk. Bu nedenle; ELISA ile serum VEGF kolay tespit edilmesi, daha büyük ve çok değişkenli çalışmalarda önemi gösterildikten sonra, yararlı bir klinik parametre olabilir.

PDF

___

1. Cheson B, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87(12): 4990-4997.

2. Rozman C, Montserrat E. Current concepts: chronic lymphocytic leukemia. N Engl J Med. 1995; 333(16): 1052-1057.

3. Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia Hematology Am Soc Hematol Educ Program. 2015;2015:368-77.

4. Rai Kr, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2): 219-234.

5. Binet J, Augier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48(1): 198-206.

6. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R,et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338(21): 1506-1514.

7. Schweighofer CD, Cymbalista F, Muller C, Busch R, Porcher R,Langerbeins P et al. Early versus deferredtreatment with combined fludarabine, cyclophosphamide and rituximab(FCR) improves event-free survival in patients with high-risk Binet A chronic lymphocytic leukemia—first results of a randomized German-French cooperative phase III trial. Blood. 2013;122(21).

8. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biology insights into clinical practice for patients with CLL. Blood. 2004; 103(4): 1202-1210.

9. Amaya-Chanaga CI, Rassenti LZ. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. Best Pract Res Clin Haematol. 2016 ;29(1):79-89.

25. 10.Montillo M, Hamblin T, Hallek M, , Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005; 90(3): 391-399.

10. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010(1):481-488.

26. 12.Shanafelt TD, KayNE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol. 2006 Apr;33(2):174-85.

13. Aguirre Palma LM, Gehrke I, Kreuzer KA. Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand ? Crit Rev Oncol Hematol. 2015 ;93(3):225-36.

14. Molica S, Vitelli G, Levato D, Ricciotti A , Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B- cell chronic lymphocyctic leukemia. Br J Cancer. 2002; 86(1): 31-35.

15. Molica S, Vacca A, Ribatti D,Cuneo A, Cavazzini F, Levato D et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002; 100(9): 3344-3351.

16. Antic D, Mihaljevic B, Cokic V, Fekete MD, Djurasevic TK, Pavlovic S, et al. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. Leuk Lymphoma. 2011 Jul;52(7):1394-7.

17. Rozman C, Montserrat E. Bone marrow biopsy in chronic lymphocytic leukemia.Nouv Rev Fr Hematol. 1988;30(5-6):369-71.

18. Dighiero G. CLL biology and prognosis. Hematology Am Soc Hematol Educ Program. 2005;:278-84.

19. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014 Dec 3;312(21):2265-76.

20. Xia Y, Lu RN, Li J. Angiogenic factors in chronic lymphocytic leukemia.Leuk Res. 2012 Oct;36(10):1211-7.

21. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002 27;417(6892):954-8.

22. Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA. Bone marrow stromal cellderived vascular endothelial growth factor (VEGF) rather than chroniclymphocytic leukemia (CLL) cellderived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med. 2011;17(7-8):619-27

23. Peterson L, Kini AR. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood. 2001; 97(8): 2529.

24. Maffei R, Martinelli S, Castelli I, Santachiara R, Zucchini P, Fontana M, et al.Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res. 2010 Mar;34(3):312-21.

25. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000;14:1414– 1418.

26. Molica S, Cutrona G, Vitelli G, Mirabelli R, Molica M, Digiesi G,et al. Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early Bcell chronic lymphocytic leukemia. Leuk Res. 2007;31:1575–1578.

27. Smolej L, Andrys C, Peková S, Schwarz J, Belada D, Zák P. Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia. Haematologica 2006;91:1432–3.

28. McCabe D, Bacon L, O’Regan K, Condron C, O’Donnell JR, Murphy PT. CD38 expression on Bcell chronic lymphocytic leukemic cells is strongly correlated with vascular endothelial growth factor expression. Leukemia 2004;18: 649–50.

29. Maffei R, Marasca R, Martinelli S, Castelli I, Santachiara R, Morandi E, et al. Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. Leukemia 2007;21:1312–5.

30. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000; 96(6): 2240-2245.